Syndax Pharmaceuticals Long Term Debt

As of the most recent data (June 2026), SNDX shows a long-term debt of $590M. That compares with $1.3M in the prior-year period — up 44343.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SNDX's long-term debt is now $590M (was $1.3M) — a 44343.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Syndax Pharmaceuticals is outperforming or lagging.

Tracking SNDX's long-term debt over time shows whether Syndax Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $590M That compares with $1.3M in the prior-year period — up 44343.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Syndax Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $590M) with ownership activity and broader fundamentals.

Syndax Pharmaceuticals's long-term debt is $590M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.